Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers
Latest Information Update: 18 Nov 2021
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms MoST addendum 2
- 03 May 2021 Planned End Date changed from 28 Feb 2020 to 31 Jul 2022.
- 03 May 2021 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2019 Planned number of patients changed from 64 to 112.